Source: Myriad Genetics, Inc.

Myriad Genetics to Present Three Studies at the 2017 National Society of Genetic Counselors Annual Conference

Important Data will Highlight riskScore™, a New Innovative Test to Assess the Breast Cancer Risk for Patients Testing Negative with myRisk® Hereditary Cancer Test

SALT LAKE CITY, Sept. 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present results from three studies at the National Society of Genetic Counselors (NSGC) Annual Conference to be held September 13-16, 2017, in Columbus, OH.  Importantly, Myriad will present results from a study with 17,205 patients designed to validate a panel of single nucleotide polymorphisms (SNPs) across the entire human genome that are associated with increased breast cancer risk.

“As we announced earlier this month, we launched an exciting new product called riskScore™ to help women who test negative for a hereditary mutation understand their remaining 5-year and lifetime risk for developing breast cancer.  This important new product underscores Myriad’s commitment to scientific discovery and innovation, and expands our leadership in hereditary cancer testing,” said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetics.  “In addition to presenting exciting new data on riskScore at NSGC this year, we also will present important research regarding variant classification from our myRisk Hereditary Cancer test.”

A list of Myriad presentations at NSGC 2017 is below. More information about the company’s presentations can be found at:  Follow Myriad on Twitter via @MyriadGenetics and stay informed about conference news and updates by using the hashtag #NSGC17.




Podium Presentation
Development and Validation of a Residual Risk
Score to Predict Breast Cancer Risk in
Unaffected Women Negative for Mutations on a    
Multi-Gene Hereditary Cancer Panel
Sept. 16,
2017: 11:30-    
11:45 a.m.

Variant Reclassification in a Clinical Cohort: A
Decade of Experience
Sept. 15,
2017: 3:15-
3:30 p.m.
Poster Presentations
Hereditary cancer panel testing allows a
screening opportunity for Hereditary Breast and  
Ovarian Cancer and Lynch Syndrome
regardless of the testing indication




Sept. 14,
2017: 5:45-
7:00 p.m.

About riskScore
riskScore is a new clinically validated personalized medicine tool that enhances Myriad’s myRisk® Hereditary Cancer test.  riskScore helps to further predict a women’s lifetime risk of developing breast cancer using clinical risk factors and genetic-markers throughout the genome. The test incorporates data from greater than 80 single nucleotide polymorphisms identified through 20 years of genome wide association studies in breast cancer and was validated in our laboratory to predict breast cancer risk. This data is then combined with a best-in-class family and personal history algorithm, the Tyrer-Cuzick model, to provide every patient with individualized breast cancer risk. riskScore is offered free-of-charge as an added service to Myriad’s myRisk Hereditary Cancer test.

About Myriad myRisk® Hereditary Cancer
The Myriad myRisk Hereditary Cancer test uses an extensive number of sophisticated technologies and proprietary algorithms to evaluate 28 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma. 

About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on five strategic imperatives:  stabilizing hereditary cancer revenue, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020.  For more information on how Myriad is making a difference, please visit the Company's website:

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to data being presented at the at the 2017 National Society of Genetic Counselors Annual Conference being held September 13-16, 2017 in Columbus, OH; the ability of the riskScore test to help women who test negative for a hereditary mutation understand their remaining 5-year and lifetime risk for developing breast cancer; Myriad’s commitment to scientific discovery and innovation, and leadership in hereditary cancer testing; research regarding variant classification concerning our myRisk Hereditary Cancer test; and the Company’s strategic directives under the caption “About Myriad Genetics.” These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our most recent Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

Media Contact:
Ron Rogers
(801) 584-3065

Investor Contact:
Scott Gleason
(801) 584-1143